Enhancement of Mdr2 Gene Transcription Mediates the Biliary Transfer of Phosphatidylcholine Supplied by an Increased Biosynthesis in the Pravastatin-treated Rat
Overview
Affiliations
An increase of biliary lipid secretion is known to occur in the rat under sustained administration of statin-type 3-hydroxy-3-methylglutaryl (HMG) coenzyme A (CoA) reductase inhibitors. The present study has addressed critical mechanisms of hepatic lipid synthesis and phosphatidylcholine (PC) biliary transport in the rat fed with a 0.075% pravastatin diet for 3 weeks. After treatment, biliary secretion of PC and cholesterol increased to 233% and 249% of controls, while that of bile salts was unchanged. Activity of cytidylyltransferase (CT), a major regulatory enzyme in the CDP-choline pathway of PC synthesis, was raised in both microsomal and cytosolic fractions (226% and 150% of controls), and there was an increase to 187% in the mass of active enzyme as determined by Western blot of microsomal protein using an antibody specific to CT. Cytosolic activity of choline kinase, another enzyme of the CDP-choline pathway, also increased to 175% of controls. In addition, there was an over eightfold increase in the HMG CoA reductase activity and mRNA. Thus, an increased PC and cholesterol synthetic supply to hepatocytes appeared as a basic mechanism for the biliary hypersecretion of these lipids. Notwithstanding the increased synthesis, hepatic PC content was unchanged, suggesting an enhanced transfer of this lipid into bile. Indeed, there was a sevenfold increase of multidrug resistance gene 2 (mdr2) gene mRNA coding for a main PC canalicular translocase. Thus, hypersecretion of biliary PC in the model studied can be explained by an up-regulation of mdr2 gene transcription and its P-glycoprotein product mediating the biliary transfer of PC supplied by an increased biosynthesis.
Nuclear receptors as drug targets in cholestatic liver diseases.
Halilbasic E, Baghdasaryan A, Trauner M Clin Liver Dis. 2013; 17(2):161-89.
PMID: 23540496 PMC: 3633080. DOI: 10.1016/j.cld.2012.12.001.
Influence of multidrug resistance on (18)F-FCH cellular uptake in a glioblastoma model.
Vanpouille C, Le Jeune N, Kryza D, Clotagatide A, Janier M, Dubois F Eur J Nucl Med Mol Imaging. 2009; 36(8):1256-64.
PMID: 19300998 DOI: 10.1007/s00259-009-1101-5.
Nuclear receptors as therapeutic targets in cholestatic liver diseases.
Zollner G, Trauner M Br J Pharmacol. 2009; 156(1):7-27.
PMID: 19133988 PMC: 2697779. DOI: 10.1111/j.1476-5381.2008.00030.x.
Kok T, Bloks V, Wolters H, Havinga R, Jansen P, Staels B Biochem J. 2002; 369(Pt 3):539-47.
PMID: 12381268 PMC: 1223107. DOI: 10.1042/BJ20020981.